1. Home
  2. ELVN vs PDM Comparison

ELVN vs PDM Comparison

Compare ELVN & PDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVN
  • PDM
  • Stock Information
  • Founded
  • ELVN 2016
  • PDM 1997
  • Country
  • ELVN United States
  • PDM United States
  • Employees
  • ELVN N/A
  • PDM N/A
  • Industry
  • ELVN Biotechnology: Pharmaceutical Preparations
  • PDM Building operators
  • Sector
  • ELVN Health Care
  • PDM Real Estate
  • Exchange
  • ELVN Nasdaq
  • PDM Nasdaq
  • Market Cap
  • ELVN 1.1B
  • PDM 1.1B
  • IPO Year
  • ELVN 2020
  • PDM N/A
  • Fundamental
  • Price
  • ELVN $22.00
  • PDM $8.84
  • Analyst Decision
  • ELVN Strong Buy
  • PDM Buy
  • Analyst Count
  • ELVN 5
  • PDM 3
  • Target Price
  • ELVN $37.80
  • PDM $10.67
  • AVG Volume (30 Days)
  • ELVN 235.9K
  • PDM 695.7K
  • Earning Date
  • ELVN 03-13-2025
  • PDM 02-13-2025
  • Dividend Yield
  • ELVN N/A
  • PDM 5.65%
  • EPS Growth
  • ELVN N/A
  • PDM N/A
  • EPS
  • ELVN N/A
  • PDM N/A
  • Revenue
  • ELVN N/A
  • PDM $572,424,000.00
  • Revenue This Year
  • ELVN N/A
  • PDM N/A
  • Revenue Next Year
  • ELVN N/A
  • PDM $0.18
  • P/E Ratio
  • ELVN N/A
  • PDM N/A
  • Revenue Growth
  • ELVN N/A
  • PDM N/A
  • 52 Week Low
  • ELVN $10.90
  • PDM $5.93
  • 52 Week High
  • ELVN $30.03
  • PDM $11.12
  • Technical
  • Relative Strength Index (RSI)
  • ELVN 44.95
  • PDM 47.54
  • Support Level
  • ELVN $20.92
  • PDM $8.45
  • Resistance Level
  • ELVN $23.08
  • PDM $8.93
  • Average True Range (ATR)
  • ELVN 1.62
  • PDM 0.24
  • MACD
  • ELVN -0.06
  • PDM 0.04
  • Stochastic Oscillator
  • ELVN 35.32
  • PDM 59.00

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

About PDM Piedmont Office Realty Trust Inc.

Piedmont Office Realty Trust Inc is a real estate investment trust engaged in the acquisition, development, and management of commercial real estate properties throughout the U.S. The company's real estate portfolio is mainly composed of office properties located in the majority of American metropolitan areas. Piedmont derives majority of its revenue in the form of rental income from tenants in mid- to long-term lease agreements. The vast majority of the company's revenue comes from the leasing of its assets in Washington D.C., New York City, Chicago, Atlanta, Minneapolis, Dallas, and Boston. Piedmont's large customers in terms of rental revenue are U.S. Government entities, business services companies, and financial institutions.

Share on Social Networks: